Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Pembrolizumab and Liver-Directed Therapy or Peptide Receptor Radionuclide Therapy for Patients With Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Metastases

NCT03457948 is registered in ClinicalTrials.gov with Nicholas Fidelman, MD as lead sponsor.

NCT NCT03457948
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03457948 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Pembrolizumab and Liver-Directed Therapy or Peptide Receptor Radionuclide Therapy for Patients With Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Metastases
Lead sponsor
Nicholas Fidelman, MD
Phase
Phase 2
Overall status
Completed
Start date
August 27, 2018
Completion date
May 31, 2026
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic malignant neoplasm in the liver, neuroendocrine neoplasm